Evaluation of Extended Intravenous of Beta-lactams in the Treatment of Serious Gram-negative Infections in Critically Ill Patients
NCT ID: NCT01600768
Last Updated: 2012-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2012-02-29
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Cohort Study on Anti-microbial Stewardship in PICU
NCT05862688
Bloodstram Infections in ICU. Single Centre Observational Study.
NCT04926935
Gram-negative Bacilli and MRSA Screening in ICU in China
NCT04310722
Chlorhexidine to Prevent Catheter-related Urinary Tract Infection
NCT05712434
Antimicrobials Stewardship by Pharmacist
NCT02768454
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intermittent infusion
Beta-Lactams
infusion time: 30 mins or 1 hr
extended infusion
Beta-Lactams
infusion time 4 hrs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Beta-Lactams
infusion time: 30 mins or 1 hr
Beta-Lactams
infusion time 4 hrs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted on the intensive care unit
* Starting a treatment with beta-lactams antibiotics
* Signed informed consent
* Expected to live \> 3 days
Exclusion Criteria
* renal replacement therapy
* ANC \< 1000 103 µl
* pregnancy
* drug abuse
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shu-Wen Lin, Pharm D.
Role: PRINCIPAL_INVESTIGATOR
National Taiwan University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NTUH
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
200912104M
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.